Login
$FBIO
$1.71 -$0.17 (9.04%) Live

$FBIO SEC Filings

Filed On Filing
13 Nov 2026 10-Q
13 Nov 2026 8-K: Results of Operations and Financial Condition

Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026 compared to the third quarter of 2025

29 Oct 2026 SCHEDULE 13G/A
01 Oct 2026 8-K: Other Events

As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the “Company”), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “Oaktree Agreement”)...

01 Oct 2026 Form 4: Jin David, Chief Financial Officer

Received 1,190 shares as a grant or award ($2.16K)

01 Sep 2026 SCHEDULE 13G
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025

24 Jun 2026 Form 4: Jin David, Chief Financial Officer

Received 400,000 shares as a grant or award

23 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, Fortress Biotech, Inc. (the “Company” or “Fortress”) held its annual meeting of stockholders (the “2026 Annual Meeting”) at 10:00 a.m. Eastern Time by means of an online virtual meeting platform.

15 May 2026 SCHEDULE 13G/A
14 May 2026 10-Q
14 May 2026 8-K: Results of Operations and Financial Condition

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million

28 Apr 2026 DEFA14A
28 Apr 2026 Proxy statement: annual meeting on June 17, 2026

CEO pay $2.9M, up 109%

01 Apr 2026 Form 4: Jin David, Chief Financial Officer

Received 2,967 shares as a grant or award ($6.46K)

31 Mar 2026 10-K
31 Mar 2026 8-K: Results of Operations and Financial Condition

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million; Cyprium is also eligible to ...

30 Mar 2026 8-K: Other Events

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

20 Mar 2026 Form 4: Rosenwald Lindsay A Md, Director

Received 475,424 shares as a grant or award

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support